G. Botwin

发表

Evaluation of direct-to-consumer low-volume lab tests in healthy adults.

Li Li, Joel T Dudley, Eric E Schadt, 2016, The Journal of clinical investigation.

An Opportune and Relevant Design for Studying the Health Trajectories of Healthcare Workers

C. Goldzweig, C. Albert, D. McGovern, 2020, medRxiv.

Update on Recently Approved Treatments for Hepatitis C

T. Morgan, G. Botwin, D. Chao, 2014, Current Treatment Options in Gastroenterology.

The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders

D. McGovern, Dalin Li, R. Gittelman, 2021, medRxiv.

Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease

S. Targan, E. Vasiliauskas, D. McGovern, 2021, Gastroenterology.

Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease

D. McGovern, Susan Cheng, Dalin Li, 2021, The American journal of gastroenterology.

NOD2 contributes to cutaneous defense against Staphylococcus aureus through α-toxin-dependent innate immune activation

V. Nizet, J. Hugot, M. Karin, 2009, Proceedings of the National Academy of Sciences.

A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis

N. Kaplowitz, S. Hamal, T. Morgan, 2022, EClinicalMedicine.

Bacterial infections in cirrhosis

T. Morgan, G. Botwin, 2014, Hepatology International.

Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease

D. McGovern, Dalin Li, G. Melmed, 2021, Annals of Internal Medicine.

Sleep in the Natural Environment: A Pilot Study

Fayzan F. Chaudhry, M. Danieletto, J. Dudley, 2020, Sensors.

Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer

D. McGovern, R. Paquette, J. V. Van Eyk, 2021, Cancer Research.

Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease

J. Danesh, M. Daly, J. Stelling, 2020, Nature Communications.

Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease

D. McGovern, Dalin Li, R. Gittelman, 2022, Frontiers in Immunology.

Genome‐wide Association Study and Meta‐analysis on Alcohol‐Associated Liver Cirrhosis Identifies Genetic Risk Factors

J. Whitfield, M. Pirmohamed, H. Cordell, 2020, Hepatology.

Brief Report: Genetics of Alcoholic Cirrhosis—GenomALC Multinational Study

J. Whitfield, H. Cordell, T. Foroud, 2015, Alcoholism, clinical and experimental research.

Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease

Alka A. Potdar, M. Daly, S. Targan, 2020, Gastroenterology.

Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers: a cross-sectional study

C. Albert, D. McGovern, W. Tourtellotte, 2021, BMJ Open.

Prevalence and Effect of Genetic Risk of Thrombo-embolic Disease in Inflammatory Bowel Disease.

M. Daly, C. Stevens, D. McGovern, 2020, Gastroenterology.

A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.

J. Whitfield, M. Pirmohamed, A. McQuillin, 2021, Journal of hepatology.

S878 Patient Reported Outcomes (PRO2) Are a Sensitive Measure of Endoscopic Disease Activity in Ulcerative Colitis

S. Dube, C. Landers, G. Melmed, 2021, American Journal of Gastroenterology.

Patient Reported Outcomes (PRO2) Are a Sensitive Measure of Endoscopic Disease Activity in Ulcerative Colitis

S. Dube, C. Landers, G. Melmed, 2021 .

The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy

D. McGovern, Dalin Li, R. Gittelman, 2022, Inflammatory bowel diseases.

Symptomology following mRNA vaccination against SARS-CoV-2

D. McGovern, H. Aronow, B. Coleman, 2021, Preventive Medicine.

Estimating the scale of COVID-19 Epidemic in the United States: Simulations Based on Air Traffic directly from Wuhan, China

Jun Lv, Dalin Li, Liming Li, 2020, medRxiv.

Reduced expression of COVID-19 host receptor, ACE2 is associated with small bowel inflammation, more severe disease, and response to anti-TNF therapy in Crohn’s disease

Alka A. Potdar, S. Targan, D. McGovern, 2020, medRxiv.

Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn’s disease and leads to impaired CFB cleavage and phagocytosis

Judy H. Cho, Alka A. Potdar, J. Rioux, 2023, Gut.

Treatment of alcoholic hepatitis

G. Botwin, D. Chao, T. Morgan, 2013, Clinical liver disease.

Adverse Events Following SARS-CoV-2 mRNA Vaccination Among Patients with Inflammatory Bowel Disease

D. McGovern, G. Melmed, J. Figueiredo, 2021, medRxiv.

SARS-CoV-2 Seroprevalence Across a Diverse Cohort of Healthcare Workers

C. Albert, D. McGovern, W. Tourtellotte, 2020, medRxiv.

Sex-Dimorphic Analyses Identify Novel and Sex-Specific Genetic Associations in Inflammatory Bowel Disease.

Alka A. Potdar, S. Dube, G. Boucher, 2023, Inflammatory bowel diseases.

Evaluation of direct-to-consumer low-volume lab tests in healthy adults.

E. Schadt, J. Dudley, Noah Zimmerman, 2016, The Journal of clinical investigation.

Serum Analyte Profiles Associated With Crohn's Disease and Disease Location.

Judy H. Cho, Claire L. Simpson, J. Rioux, 2021, Inflammatory bowel diseases.

Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors

H. Cordell, P. Nahon, R. Moirand, 2023 .

A blood-based transcriptomic signature stratifies severe Crohn’s disease and defines potentially targetable therapeutic pathways

Alka A. Potdar, S. Targan, D. McGovern, 2023, Frontiers in Gastroenterology.